Sugi Predict

Sugi Predict / Compounds / SCHEMBL763023

SCHEMBL763023

SCHEMBL763023

O=c1c2nn(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2ncn1CC(F)(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316565 0.92 CNR1 (0.85) CNR1
SCHEMBL4819820 0.92 CNR1 (1.00) CNR1
SCHEMBL4816565 0.87 CNR1 (0.77) CNR1
SCHEMBL4821944 0.87 CNR1 (0.76) CNR1
SCHEMBL4823830 0.87 CNR1 (0.76) CNR1
SCHEMBL4822362 0.86 CNR1 (0.75) CNR1
SCHEMBL4823932 0.83 CNR1 (1.00) CNR1
SCHEMBL4818656 0.83 CNR1 (0.71) CNR1
SCHEMBL4821177 0.82 CNR1 (0.69) CNR1
SCHEMBL4819803 0.81 CNR1 (0.81) CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141669-B2 Cannabiniod receptor ligands and uses thereof PFIZER INC. (US) 2006-11-28 — — US claimed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 — — US claimed
US-8138174-B2 Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders SOLVAY PHARMACEUTICALS B.V. (NL) 2012-03-20 — — US disclosed
US-8138174-B2 Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders SOLVAY PHARMACEUTICALS B.V. (NL) 2012-03-20 — — US disclosed
US-8063062-B2 Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction; -chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazolyl]-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino]methylene}benzene-sulfonamide SOLVAY PHARMACEUTICALS B.V. (NL) 2011-11-22 — — US disclosed
US-8063062-B2 Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction; -chloro-N-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazolyl]-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptylamino]methylene}benzene-sulfonamide SOLVAY PHARMACEUTICALS B.V. (NL) 2011-11-22 — — US disclosed
EP-2091939-B1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-03-16 — — EP disclosed
WO-2008084057-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARMACEUTICALS B.V. (NL) 2008-07-17 — — WO disclosed
US-20080153867-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION SOLVAY PHARMACEUTICALS B.V. 2008-06-26 — — US disclosed
US-20080153867-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION SOLVAY PHARMACEUTICALS B.V. 2008-06-26 — — US disclosed
WO-2008074816-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION SOLVAY PHARMACEUTICALS B.V. (NL) 2008-06-26 — — WO disclosed
US-7354929-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2008-04-08 — — US disclosed
US-7354929-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2008-04-08 — — US disclosed
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER INC 2007-05-10 — — US disclosed
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER INC 2007-05-10 — — US disclosed
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER INC 2007-05-10 — — US disclosed
US-7141669-B2 Cannabiniod receptor ligands and uses thereof PFIZER INC. (US) 2006-11-28 — — US disclosed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 — — US disclosed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 — — US disclosed
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-10-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105856-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, GPR18 CNR1 1/4885
US-20080153867-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION ACHE, BACE1, BCHE CNR1 4/4885
US-20040214838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.